Itayetzi Reyes-Avendaño

Dr. Itayetzi Reyes-Avendaño

Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, México

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
IRItayetzi Reyes-Avendaño
Itayetzi Reyes-Avendaño
EREdilburga Reyes-Jiménez
Edilburga Reyes-Jiménez
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
DPDulce Pérez-Figueroa
Dulce Pérez-Figueroa
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Hepatocellular carcinoma (HCC) is a health problem worldwide due to its high mortality rate, and the tumor microenvironment (TME) plays a key role in the HCC progression. The current ineffective therapies to fight the disease still warrant the development of preventive strategies. Quercetin has been shown to have different antitumor activities; however, its effect on TME components in preneoplastic lesions has not been fully investigated yet. Here, we aimed to evaluate the effect of quercetin (10 mg/kg) on TME components during the early stages of HCC progression induced in the rat. Histopathological and immunohistochemical analyses showed that quercetin decreases the size of preneoplastic lesions, glycogen and collagen accumulation, the expression of cancer stem cells and myofibroblasts markers, and that of the transporter ATP binding cassette subfamily C member 3 (ABCC3), a marker of HCC progression and multi-drug resistance. Our results strongly suggest that quercetin has the capability to reduce key components of TME, as well as the expression of ABCC3. Thus, quercetin can be an alternative treatment for inhibiting the growth of early HCC tumors.

Verified
Journal Article
Open access
PDF file
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
IRItayetzi Reyes-Avendaño
Itayetzi Reyes-Avendaño
JSJovito Santos
Jovito Santos
EREdilburga Reyes-Jiménez
Edilburga Reyes-Jiménez
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible disease with a high mortality rate worldwide. However, the etiology and pathogenesis of IPF have not yet been fully described. Moreover, lung cancer is a significant complication of IPF and is associated with increased mortality. Nevertheless, identifying common genes involved in developing IPF and its progression to lung cancer remains an unmet need. The present study aimed to identify hub genes related to the development of IPF by meta-analysis. In addition, we analyzed their expression and their relationship with patients’ progression in lung cancer. Method: Microarray datasets GSE24206, GSE21369, GSE110147, GSE72073, and GSE32539 were downloaded from Gene Expression Omnibus (GEO). Next, we conducted a series of bioinformatics analysis to explore possible hub genes in IPF and evaluated the expression of hub genes in lung cancer and their relationship with the progression of different stages of cancer. Results: A total of 1888 differentially expressed genes (DEGs) were identified, including 1105 upregulated and 783 downregulated genes. The 10 hub genes that exhibited a high degree of connectivity from the PPI network were identified. Analysis of the KEGG pathways showed that hub genes correlate with pathways such as the ECM–receptor interaction. Finally, we found that these hub genes are expressed in lung cancer and are associated with the progression of different stages of lung cancer. Conclusions: Based on the integration of GEO microarray datasets, the present study identified DEGs and hub genes that could play an essential role in the pathogenesis of IPF and its association with the development of lung cancer in these patients, which could be considered potential diagnostic biomarkers or therapeutic targets for the disease.

8 September 2025 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
IRItayetzi Reyes-Avendaño
Itayetzi Reyes-Avendaño
Victor Acevedo-SánchezVictor Acevedo-Sánchez
Victor Acevedo-Sánchez
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Tenascin-C (TNC) is an extracellular matrix (ECM) protein with key roles in various biological processes, such as embryonic development and tissue regeneration. However, its deregulated expression can contribute to pathological responses, promoting chronic inflammation, fibrosis, or tumor progression. It belongs to the tenascin family, a class of extracellular proteins that interfere with cellular events in both physiological and pathological contexts, interacting specifically with cells and other components of the ECM. TNC has emerged as a key player in the pathogenesis of chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease (COPD), lung cancer (LC), pulmonary hypertension (PH), and idiopathic pulmonary fibrosis (IPF). The influence of TNC on cellular responses, which is mediated by precise interactions with cellular receptors and ligands, triggers complex intracellular signaling cascades associated with the inflammatory response, fibrosis, and tumorigenesis in these CRDs. This review synthesizes recent evidence highlighting the multifaceted roles and underlying mechanisms of TNC in the context of these CRDs.

30 June 2026 in Biology
Verified
Journal Article
Open access
PDF file
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
DGDulce Natividad Jiménez Gómez
Dulce Natividad Jiménez Gómez
AHAlma Aurora Ramírez Hernández
Alma Aurora Ramírez Hernández
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by high mortality and marked clinical heterogeneity. A defining yet insufficiently understood feature of IPF is its frequent coexistence with pulmonary and extrapulmonary comorbidities. However, the molecular basis that underlies this multisystem involvement remains unclear. We applied an integrative systems-level framework that combines lung-derived transcriptomic datasets with curated disease–gene associations across major IPF-associated comorbidities. Network organization and functional stratification analyses were used to characterize shared and disease-specific molecular modules, and independent transcriptomic datasets were analyzed to evaluate the consistency of these patterns. These analyses revealed structured molecular convergence between IPF and its comorbidities organized into two interacting biological programs: a lung-enriched fibrotic–mechanical program and a systemically distributed neuroimmune–metabolic program. These programs are interconnected through a shared regulatory interface that includes IL6, AKT1, TGFB1 and STAT3. This organization was consistently observed across independent datasets. IPF emerges from the interaction between pulmonary and systemic regulatory programs rather than isolated lung-restricted mechanisms. This framework provides a basis for understanding disease heterogeneity and comorbidity burden, with potential implications for stratification and therapeutic targeting.